Completed PHASE2 INTERVENTIONAL 1-arm NCT00417274

Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer

An Open-Label, Phase II Safety, Tolerability, Drug Level and Efficacy Trial of Quinacrine in Patients With Androgen-Independent Metastatic Prostate Cancer

Sponsor: Cleveland BioLabs

Conditions Prostatic Cancer

Interventions Quinacrine

Updated 8 times since 2017 Last updated: Mar 6, 2013 Started: Dec 31, 2006 Primary completion: May 31, 2008 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Prostatic Cancer, this trial is completed. The trial is conducted by Cleveland BioLabs and has accumulated 8 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cleveland BioLabs

Data source: Cleveland BioLabs

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.